|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.23/-0.25
|
企业价值
13.28B
|
资产负债 |
每股账面净值
0.59
|
现金流量 |
现金流量率
--
|
损益表 |
收益
17.50M
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/23 22:19 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |